Delivering Evidence Based Care Using Artificial Intelligence to Patients With Diabetes and CardioVascular Comorbidities: The DECIDE-CV Innovation Project
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 210
- 试验地点
- 1
- 主要终点
- Presence or absence of T2DM
研究概览
简要总结
The purpose of this study is to identify digital biomarkers associated with type 2 diabetes mellitus (T2DM) by combining sensor data from a wrist-worn wearable and clinical data. This will be done by recruiting patients with and without diabetes within the cardio-metabolic clinics a the MUHC. Consented patients will be provided with a HOP Technologies (HOP) watch in this project across two observation periods. The Watch-HOP platform facilitates the development of predictive algorithms built with data collected in a clinical setting or at home in a passive (sensors) and active (self-assessments) way. Data from the Watch-Hop will be analyzed using machine learning strategies to determine associations with clinical measures of T2DM.
详细描述
The epidemic of type 2 diabetes mellitus (T2DM) continues to increase. Sensor technologies and artificial intelligence present us with an opportunity to identify patients suffering from T2DM and to optimize their treatment.
Specifically, our primary objective is to identify digital biomarkers associated with T2DM by combining sensor data from a wrist-worn wearable and clinical data.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age > 18 years
- •Able to follow-up with study protocol schedule
- •Life expectancy > 1 year
- •Case group only a. HbA1c >= 6.5% or is diagnosed with T2DM
排除标准
- •Any person who does not meet the above criteria or who refuses to participate
- •Undergoing chemotherapy or dialysis
- •Currently in palliative care
- •Any person who does not have an email address
- •Control group only a. HbA1c >= 6.5% or is diagnosed with T2DM
结局指标
主要结局
Presence or absence of T2DM
时间窗: Cross sectional based on a single clinic visit with device worn for an estimated 24 hours
As defined by HbA1c \> 6.5 %, known history of T2DM, or on antihyperglycemic therapies
Glycemic control amongst people with established T2DM.
时间窗: Cross sectional based on a single clinic visit with device worn for an estimated 24 hours
As defined by HbA1c %
次要结局
- Glycemic control.(Cross sectional based on a single clinic visit with device worn for an estimated 24 hours)
- Change in glycemic control.(On average the change will be evaluated over 3-6 months)
研究者
Abhinav Sharma
Assistant Professor
McGill University Health Centre/Research Institute of the McGill University Health Centre